Altimmune (ALT) to Release Quarterly Earnings on Tuesday

Altimmune (NASDAQ:ALT - Get Free Report) will issue its quarterly earnings data before the market opens on Tuesday, November 12th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The business had revenue of $0.01 million during the quarter. Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. During the same quarter in the prior year, the company posted ($0.32) earnings per share. On average, analysts expect Altimmune to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Altimmune Stock Performance

Shares of NASDAQ:ALT traded up $0.09 during midday trading on Tuesday, hitting $6.88. The company's stock had a trading volume of 1,193,854 shares, compared to its average volume of 3,766,829. The business's 50 day simple moving average is $6.76 and its 200 day simple moving average is $6.85. The company has a market cap of $488.96 million, a P/E ratio of -4.19 and a beta of 0.09. Altimmune has a 12-month low of $2.32 and a 12-month high of $14.84.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on ALT shares. Evercore ISI raised shares of Altimmune to a "strong-buy" rating in a research note on Friday, August 9th. B. Riley reissued a "buy" rating and issued a $20.00 price target on shares of Altimmune in a research note on Monday, August 12th. Finally, HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Altimmune in a research note on Thursday, August 22nd. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $18.80.

Insider Activity

In other news, Director David Drutz sold 16,011 shares of the company's stock in a transaction on Monday, August 19th. The shares were sold at an average price of $6.90, for a total value of $110,475.90. Following the completion of the transaction, the director now owns 41,958 shares in the company, valued at approximately $289,510.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 4.10% of the company's stock.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.